INCYIncyte CorporationFinished
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).
Squamous Cell Carcinoma of the Anal Canal
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 308 (final count)
- Started
- Nov 9, 2020
- Main results expected
- Apr 15, 2024
- Fully finished
- Sep 26, 2025
- Results posted
- May 23, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS)
Measured over: up to 33.9 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04472429 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC